BIOMAT Database Logo BIOMAT Database Logo

Plasma levels of atrial natriuretic peptide in patients with liver cirrhosis and its relation to ascites and renal function. 1989

H Fukui, and T Tsujii, and M Matsumura, and S Okamoto, and T Morita, and M Koizumi, and M Morimura, and H Kojima, and Y Hokaze, and M Fujimoto
Third Department of Internal Medicine, Nara Medical University, Japan.

Plasma immunoreactive alpha-human atrial natriuretic polypeptide (Ir-alpha-hANP) was measured by radioimmunoassay in 21 cirrhotics and 10 normal subjects. Average of Ir-alpha-hANP level in cirrhotics was significantly higher than in normal subjects (125.8 +/- 79.6 versus 28.7 +/- 12.2 pg/ml, P less than 0.001). In cirrhotics without ascites, Ir-alpha-hANP levels were positively correlated with creatinine clearance (Ccr) and urinary sodium excretion, suggesting that alpha-hANP was closely related to renal circulation and sodium homeostasis. On the contrary, in cirrhotics with ascites Ir-alpha-hANP levels were negatively correlated with Ccr. Urinary sodium excretion in cirrhotics with ascites and Ccr more than 50 ml/min was positively correlated with Ir-alpha-hANP levels. However, cirrhotics with ascites and Ccr less than 50 ml/min excreted little sodium in spite of high Ir-alpha-hANP levels. On the basis of the Ir-alpha-hANP before and after treatment of ascites, cirrhotics with ascites were subdivided into 2 groups. In group I Ir-alpha-hANP decreased from high values and in group II it was further elevated from slightly high values by treatment. The difference in renal function and plasma volume may account for the difference in Ir-alpha-hANP changes in the 2 groups.

UI MeSH Term Description Entries
D007668 Kidney Body organ that filters blood for the secretion of URINE and that regulates ion concentrations. Kidneys
D008103 Liver Cirrhosis Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules. Cirrhosis, Liver,Fibrosis, Liver,Hepatic Cirrhosis,Liver Fibrosis,Cirrhosis, Hepatic
D008104 Liver Cirrhosis, Alcoholic FIBROSIS of the hepatic parenchyma due to chronic excess ALCOHOL DRINKING. Alcoholic Cirrhosis,Hepatic Cirrhosis, Alcoholic,Alcoholic Hepatic Cirrhosis,Alcoholic Liver Cirrhosis
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009318 Natriuresis Sodium excretion by URINATION. Natriureses
D009320 Atrial Natriuretic Factor A potent natriuretic and vasodilatory peptide or mixture of different-sized low molecular weight PEPTIDES derived from a common precursor and secreted mainly by the HEART ATRIUM. All these peptides share a sequence of about 20 AMINO ACIDS. ANF,ANP,Atrial Natriuretic Peptide,Atrial Natriuretic Peptides,Atriopeptins,Auriculin,Natriuretic Peptides, Atrial,ANF (1-126),ANF (1-28),ANF (99-126),ANF Precursors,ANP (1-126),ANP (1-28),ANP Prohormone (99-126),ANP-(99-126),Atrial Natriuretic Factor (1-126),Atrial Natriuretic Factor (1-28),Atrial Natriuretic Factor (99-126),Atrial Natriuretic Factor Precursors,Atrial Natriuretic Factor Prohormone,Atrial Natriuretic Peptide (1-126),Atrial Pronatriodilatin,Atriopeptigen,Atriopeptin (1-28),Atriopeptin (99-126),Atriopeptin 126,Atriopeptin Prohormone (1-126),Cardiodilatin (99-126),Cardiodilatin Precursor,Cardionatrin I,Cardionatrin IV,Prepro-ANP,Prepro-CDD-ANF,Prepro-Cardiodilatin-Atrial Natriuretic Factor,Pro-ANF,ProANF,Proatrial Natriuretic Factor,Pronatriodilatin,alpha ANP,alpha-ANP Dimer,alpha-Atrial Natriuretic Peptide,beta-ANP,beta-Atrial Natriuretic Peptide,gamma ANP (99-126),gamma-Atrial Natriuretic Peptide,Natriuretic Peptide, Atrial,Peptide, Atrial Natriuretic,Peptides, Atrial Natriuretic,Prepro ANP,Prepro CDD ANF,Prepro Cardiodilatin Atrial Natriuretic Factor,Pro ANF,alpha ANP Dimer,alpha Atrial Natriuretic Peptide,beta ANP,beta Atrial Natriuretic Peptide,gamma Atrial Natriuretic Peptide
D011863 Radioimmunoassay Classic quantitative assay for detection of antigen-antibody reactions using a radioactively labeled substance (radioligand) either directly or indirectly to measure the binding of the unlabeled substance to a specific antibody or other receptor system. Non-immunogenic substances (e.g., haptens) can be measured if coupled to larger carrier proteins (e.g., bovine gamma-globulin or human serum albumin) capable of inducing antibody formation. Radioimmunoassays
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

H Fukui, and T Tsujii, and M Matsumura, and S Okamoto, and T Morita, and M Koizumi, and M Morimura, and H Kojima, and Y Hokaze, and M Fujimoto
Plasma human atrial natriuretic peptide levels in patients with liver cirrhosis.
January 1989, Journal of gastroenterology and hepatology,
H Fukui, and T Tsujii, and M Matsumura, and S Okamoto, and T Morita, and M Koizumi, and M Morimura, and H Kojima, and Y Hokaze, and M Fujimoto
Renal insensitivity to atrial natriuretic peptide in patients with cirrhosis and ascites.
November 1992, Gastroenterology,
H Fukui, and T Tsujii, and M Matsumura, and S Okamoto, and T Morita, and M Koizumi, and M Morimura, and H Kojima, and Y Hokaze, and M Fujimoto
Atrial natriuretic peptide in liver cirrhosis with mild ascites.
June 1990, Gastroenterologia Japonica,
H Fukui, and T Tsujii, and M Matsumura, and S Okamoto, and T Morita, and M Koizumi, and M Morimura, and H Kojima, and Y Hokaze, and M Fujimoto
Infusion of atrial natriuretic peptide in liver cirrhosis with ascites.
January 1985, Lancet (London, England),
H Fukui, and T Tsujii, and M Matsumura, and S Okamoto, and T Morita, and M Koizumi, and M Morimura, and H Kojima, and Y Hokaze, and M Fujimoto
Renal response to atrial natriuretic peptide in patients with advanced liver cirrhosis.
January 1988, Hepatology (Baltimore, Md.),
H Fukui, and T Tsujii, and M Matsumura, and S Okamoto, and T Morita, and M Koizumi, and M Morimura, and H Kojima, and Y Hokaze, and M Fujimoto
Plasma concentrations of atrial natriuretic peptide in patients with decompensated liver cirrhosis.
August 1989, The American journal of gastroenterology,
H Fukui, and T Tsujii, and M Matsumura, and S Okamoto, and T Morita, and M Koizumi, and M Morimura, and H Kojima, and Y Hokaze, and M Fujimoto
[Plasma levels of human atrial natriuretic polypeptide in patients with liver cirrhosis].
June 1986, Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology,
H Fukui, and T Tsujii, and M Matsumura, and S Okamoto, and T Morita, and M Koizumi, and M Morimura, and H Kojima, and Y Hokaze, and M Fujimoto
Human atrial natriuretic peptide (ANP) for the treatment of patients with liver cirrhosis and ascites.
January 1986, Klinische Wochenschrift,
H Fukui, and T Tsujii, and M Matsumura, and S Okamoto, and T Morita, and M Koizumi, and M Morimura, and H Kojima, and Y Hokaze, and M Fujimoto
Atrial natriuretic peptide in rats with experimental cirrhosis of the liver without ascites.
March 1988, Endocrinology,
H Fukui, and T Tsujii, and M Matsumura, and S Okamoto, and T Morita, and M Koizumi, and M Morimura, and H Kojima, and Y Hokaze, and M Fujimoto
Plasma levels of atrial natriuretic peptide in patients with chronic renal failure.
October 1986, The Journal of clinical endocrinology and metabolism,
Copied contents to your clipboard!